Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kuti

Showing results (251-260 of 596) with videos related to

Pageof 60
Sort By:
Pharmacotherapy|January 12, 2013
Inappropriate antibiotic use due to decreased compliance with a ventilator-associated pneumonia computerized clinical pathway: implications for continuing education and prospective feedbackAshley M Wilde, Michael D Nailor, David P Nicolau, et al.
International Journal of Antimicrobial Agents|February 22, 2016
Tissue penetration and exposure of cefepime in patients with diabetic foot infectionsWonhee So, Joseph L Kuti, Ashley Shepard, et al.
Annals of Clinical Microbiology and Antimicrobials|January 20, 2021
Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosisMaxwell J Lasko, Holly K Huse, David P Nicolau, et al.
Clinical Pharmacokinetics|October 19, 2016
Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill PatientsIris K Minichmayr, André Schaeftlein, Joseph L Kuti, et al.
The Journal of Antimicrobial Chemotherapy|July 30, 2022
Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearanceAndrew J Fratoni, John W Mah, David P Nicolau, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|August 23, 2011
Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitalsRebecca A Keel, Joseph L Kuti, Daniel F Sahm, et al.
Journal of Clinical Pharmacology|October 1, 2003
Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenemJoseph L Kuti, Prachi K Dandekar, Charles H Nightingale, et al.
Connecticut Medicine|February 3, 2004
Emerging Pseudomonas aeruginosa resistance: implications in clinical practiceChristine T Ong, Joseph L Kuti, Charles H Nightingale, et al.
Clinical Therapeutics|June 11, 2004
Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosisJoseph L Kuti, Charles H Nightingale, R Frederic Knauft, et al.
Journal of the National Medical Association|June 2, 2005
The incidence of lower mid-trunk hyperpigmentation (linea nigra) is affected by sex hormone levelsAdekunle Olufemi George, Olayiwola Babatunde Shittu, Eokezie Enwerem, et al.
Pageof 60

Showing results (251-260 of 596) with videos related to

Sort By:
Pageof 60
Pharmacotherapy|January 12, 2013
Inappropriate antibiotic use due to decreased compliance with a ventilator-associated pneumonia computerized clinical pathway: implications for continuing education and prospective feedbackAshley M Wilde, Michael D Nailor, David P Nicolau, et al.
International Journal of Antimicrobial Agents|February 22, 2016
Tissue penetration and exposure of cefepime in patients with diabetic foot infectionsWonhee So, Joseph L Kuti, Ashley Shepard, et al.
Annals of Clinical Microbiology and Antimicrobials|January 20, 2021
Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosisMaxwell J Lasko, Holly K Huse, David P Nicolau, et al.
Clinical Pharmacokinetics|October 19, 2016
Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill PatientsIris K Minichmayr, André Schaeftlein, Joseph L Kuti, et al.
The Journal of Antimicrobial Chemotherapy|July 30, 2022
Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearanceAndrew J Fratoni, John W Mah, David P Nicolau, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|August 23, 2011
Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitalsRebecca A Keel, Joseph L Kuti, Daniel F Sahm, et al.
Journal of Clinical Pharmacology|October 1, 2003
Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenemJoseph L Kuti, Prachi K Dandekar, Charles H Nightingale, et al.
Connecticut Medicine|February 3, 2004
Emerging Pseudomonas aeruginosa resistance: implications in clinical practiceChristine T Ong, Joseph L Kuti, Charles H Nightingale, et al.
Clinical Therapeutics|June 11, 2004
Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosisJoseph L Kuti, Charles H Nightingale, R Frederic Knauft, et al.
Journal of the National Medical Association|June 2, 2005
The incidence of lower mid-trunk hyperpigmentation (linea nigra) is affected by sex hormone levelsAdekunle Olufemi George, Olayiwola Babatunde Shittu, Eokezie Enwerem, et al.
Pageof 60